

Statement of Unaudited Results for the Quarter Ended June 30, 2016

(Rs. in Lakhs except earnings per share)

	Particulars	Quarter ended	Quarter ended
		June 30, 2016	June 30, 2015
		Unaudited	Unaudited
1	Income from Operations		
	(a) Sales (Inclusive of Excise Duty)	731,33	630,74
	(b) Other Operating Income	6,79	6,52
	Total Income from Operations	738,12	637,26
2	Expenses		
	(a) Cost of Materials Consumed	71,85	81,20
	(b) Purchase of Stock-in-Trade	365,92	212,97
	(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(18,37)	65,90
	(d) Employee Benefits Expense	85,81	85,83
	(e) Depreciation and Amortization Expense	4,16	3,36
	(f) Other Expenses	127,51	96,85
	Total Expenses	636,88	546,11
3	Profit from operations before Other Income, Finance Costs (1-2)	101,24	91,15
4	Other Income	13,94	12,52
5	Profit before Finance Costs (3+4)	115,18	103,67
6	Finance Costs	2	3
7	Profit before tax (5-6)	115,16	103,64
8	Tax Expense	41,15	36,33
9	Net Profit for the Period (7-8)	74,01	67,31
10	Other Comprehensive Income (after Tax)		
	- Items that will not be classified to Profit or Loss	-	(25)
	- Items that will be classified to Profit or Loss	-	-
	Total Other Comprehensive income (after Tax)	-	(25)
11	Total Comprehensive Income for the period (9+10)	74,01	67,06
12	Paid-up Equity Share Capital (Face Value Rs.10 per Equity Share)	21,25	21,25
13	Earnings Per Share (EPS) (of Rs. 10/- each) (not annualised):		
	a. Basic	34.83	31.56
	b. Diluted	34.83	31.56

SIGNED FOR IDENTIFICATION
BY 
S R B C & CO LLP
MUMBAI

Notes :


- 1 The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on August 26, 2016.
- 2 The Company operates in single reportable business segment i.e. "Pharmaceuticals" and single reportable geographical segment i.e. "Within India".
- 3 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015.
- 4 The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- 5 **Reconciliation of Net Profit between Previous GAAP and IND AS for the quarter ended June 30, 2015**

	(Rs. in Lakhs)
Net Profit under Previous GAAP	68,56
Add/(Less) : Adjustments of	
Cost of employee share based payments	(1,71)
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive Income	38
Physicians samples written off	10
Others	2
Deferred Tax on IND AS adjustments	(4)
Net Profit for the period under IND AS	67,31
Other Comprehensive Income (after Tax)	(25)
Total Comprehensive Income for the period	67,06

- 6 The Ind AS compliant corresponding figures in the previous period has not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 7 Figures for the previous period have been regrouped/reclassified wherever considered necessary.

**For and on behalf of the Board of Directors of
Abbott India Limited**

Place : Mumbai
Date : August 26, 2016




Sachin Dharap
Director
DIN : 00785700